October 01, 2020
Bankrupt biopharmaceutical company Akorn Inc. sought a Delaware court's approval late Wednesday for an at least $9 million global settlement of holdout-stockholder suits targeting the company for regulatory and data integrity failures that collapsed its $4.3 billion merger agreement with Fresenius Kabi AG in 2017.
February 06, 2020
Akorn Inc. must face two securities fraud suits over its $4.3 billion merger that imploded after regulatory violations came to light, an Illinois federal judge ruled Wednesday, finding that the generic drug-maker plausibly deceived shareholders in its financial filings.